Navigation Links
ANA598 Demonstrates SVR12 in 100% of First Group of HCV Patients Randomized to Stop All Treatment at Week 24
Date:7/29/2010

In the ongoing Phase II study, approximately 90 treatment-naive genotype 1 HCV patients have received ANA598 or placebo in combination with Pegasys® (peginterferon alfa-2a) and Copegus® (ribavirin, USP) for 12 weeks at dose levels of 200 mg bid or 400 mg bid, each with a loading dose of 800 mg bid on day one.  After week 12, patients are to continue receiving SOC.  Patients who achieved undetectable levels of virus at weeks 4 and 12 were randomized to stop all treatment at week 24 or 48.  The primary endpoint of the study is the proportion of patients who achieve undetectable levels of virus at week 12 (defined as complete Early Virological Response, or cEVR).  Additional endpoints include safety and tolerability as well as the proportion of patients with undetectable levels of virus at week 4 (defined as Rapid Virological Response, or RVR).  Patients will be followed for 24 weeks after stopping therapy to determine the rate of Sustained Virological Response, or SVR.  Approximately 90 patients have been enrolled in this study – with approximately 30 patients receiving ANA598 plus SOC at each dose level and 30 patients receiving placebo plus SOC.  The study is being managed by the Duke Clinical Research Institute (DCRI) and is being conducted at a number of clinical sites in the United States.  

About ANA598

ANA598, a direct-acting antiviral or DAA, is a non-nucleoside inhibitor of the HCV RNA polymerase and is wholly owned by Anadys.  In an ongoing Phase II study in which HCV patients received ANA598 at 200 mg bid or 400 mg bid in combination with interferon and ribavirin for twelve weeks, both dose levels showed comparable cEVR rates of 73-75% and a favorable safety profile.  In a previous Phase I study,
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
11. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Fla. , Jan. 23, 2015  Today the U.S. ... Novartis, Bexsero® for the prevention of serogroup B ... Bexsero and Pfizer,s vaccine Trumenba®, which received FDA approval ... prevent this devastating disease. "I have ...
(Date:1/23/2015)... , Jan. 23, 2015 Research and Markets ... the "Urinary Catheters Market (Indwelling or Foley Catheters, ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... , At present, the global market for ...
(Date:1/23/2015)... Inc. (NASDAQ: NWBO )("NW Bio"), a U.S. biotechnology ... solid tumor cancers, announced today that CEO Linda Powers ... Immunotherapy Forum in Washington D.C. ... January 26 at 10:30 a.m. EST at the Grand Hyatt ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3
... 21, 2011 Henry Schein, Inc. (Nasdaq: HSIC ... to office-based dental, medical and veterinary practitioners, announced that it ... response to the tragic earthquake and tsunami that hit Northern ... rest of the world, we are deeply saddened by the ...
... DETROIT, March 20, 2011 Webahn, Inc. today announced ... for physicians, now includes instant messaging capability. Capzule (capzule.com) ... small practices as a software service. Physicians ... their iPhone or iPad of items that require immediate ...
Cached Medicine Technology:Henry Schein Establishes Matching Humanitarian Relief Fund in Response to Japan Earthquake and Tsunami 2Henry Schein Establishes Matching Humanitarian Relief Fund in Response to Japan Earthquake and Tsunami 3
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many trendy ... on Facebook, Twitter, and Pinterest. The fans will have an ... lottery every week. , Moreover, the company has extended its ... Angelweddingdress homepage for more information. , Angelweddingdress is ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and David Leadbetter ... to bestow a Juvent Sports Achievement award upon an ... The award commemorated and congratulated McKitrick for her record ... her first amateur tournament in 1979 and most recently ...
(Date:1/22/2015)... over 20 years, Dr. David Cruz of Cruz Chiropractic Care ... just about every type of injury that can result from car ... twenty-plus years, the team at Doctors on Liens has ... doctor. With the combined breadth of experience between the ...
(Date:1/22/2015)... January 22, 2015 Yesterday, Senator ... (D-Concord) and Kristin Olsen (R-Modesto) were honored by ... in advancing biotechnology, biomedical science, medical device and ... each received the “2014 Life Sciences Champion” award ...
(Date:1/22/2015)... 2015 Payday lending practices in four ... cause financial distress to the states that permit them, ... University’s Center on Race and Wealth. , While they ... payday loans at the same time substantially depress economic ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... significantly contributed to the knowledge and treatment ... NEW YORK, Oct. 15 Five of ... presented to scientists of great,achievement by NARSAD, the ... an awards dinner here this Friday at the,Waldorf-Astoria ...
... bring new treatment options for patients, researchers say ... patients may one day find nicotine patches or ... researchers say. , Nicotine patches and the hot ... according to two studies presented at the American ...
... factor DMP1 as a pivotal tumor suppressor for both human ... Arf-p53 pathways. The research, published by Cell Press in the ... to development of new drug therapies for lung cancer. , ... the world, responsible for 1.3 million deaths each year. Non-small-cell ...
... Two clinical,research scientists this month joined Biomoda, Inc. ... NM, to assist with,commercialization efforts of the company,s ... technology. "Constance Dorian brings strong analytical skills ... regulations to,Biomoda. She will be an important asset ...
... announced it will host a webcast and conference call at 10 am,ET on ... which ended September 30. Financial results are,scheduled for release after the market closes ... and CEO, WHEN: Friday, November 2, 2007 ... Presentation: ...
... Group Urges Comprehensive Reform, End to Employer,Insurance ... care costs,threaten future U.S. economic growth. Today,s ... by an insurance system driven by,cost-conscious consumer ... Quality,Affordable Health Care for All: Moving Beyond ...
Cached Medicine News:Health News:NARSAD - the World's Leading Mental Health Research Charity - Presents 2007 Prizes for Outstanding Psychiatric Research at New York Gala, October 19th 2Health News:NARSAD - the World's Leading Mental Health Research Charity - Presents 2007 Prizes for Outstanding Psychiatric Research at New York Gala, October 19th 3Health News:Nicotine, Chili Peppers Offer Post-Surgery Pain Relief 2Health News:Nicotine, Chili Peppers Offer Post-Surgery Pain Relief 3Health News:DMP1 deletion cooperates with oncogenic K-ras in lung cancer 2Health News:Two Scientists Join Team of Biomoda, Inc. 2Health News:HMS Holdings Corp. Hosts Third Quarter 2007 Financial Teleconference and Presentation 2Health News:Quality, Affordable Health Care for All 2Health News:Quality, Affordable Health Care for All 3Health News:Quality, Affordable Health Care for All 4Health News:Quality, Affordable Health Care for All 5
... Recombinant immunofluorescent antibody ( RIFA:) ... semi-quantitation of human serum IgM ... antigen (VCA). Each kit contains ... recombinant EBV VCA antigen, FITC ...
When You Need Optimal Patient Comfort with Minimal Weight at a Nonunion Site...Demand The OrthoPak Noninvasive Bone Growth Stimulator., ,Most Appropriate for the Proximal Femur, Metatarsal/Tarsal...
... The StoneLight Laser System is a solid ... fragment stones in all areas of the ... tight spaces. , ,A variety of reusable ... with superior clinical versatility and outcomes. Standard ...
... CST-2000 Flexible Cystoscope System using EndoSheath ... solution for urologists in both their ... the CST-2000 flexible cystoscope with the ... between cystoscopy procedures, while minimizing the ...
Medicine Products: